NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally.
The last earnings update was 115 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NanoRepro. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NanoRepro's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoRepro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare NanoRepro's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare NanoRepro's earnings growth to the Germany market average as no estimate data is available.
Unable to compare NanoRepro's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if NanoRepro is high growth as no earnings estimate data is available.
Unable to determine if NanoRepro is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NanoRepro's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Ms. Lisa Jüngst serves as President of the Management Board at NanoRepro AG and has been its Member of Management Board since April 2013. She is Chief Executive Officer at NanoRepro AG. Ms. Jüngst served as Head of Marketing and Head of Department of Rapid Diagnostics at NanoRepro AG. Ms. Jüngst holds Diplom-Betriebswirtin Marketingleiterin. She holds a Degree in Business Administration from Fachhochschule (University of Applied Sciences) Fulda.
Insufficient data for Lisa to compare compensation growth.
Insufficient data for Lisa to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
President of the Management Board & CEO
Chief Financial Officer
Martin de Angelis
Head of the Research Board
Board of Directors
Chairman of the Supervisory Board
Deputy Chairman of Supervisory Board
Member of the Supervisory Board
Member of the Supervisory Board
Member of the Supervisory Board
Who owns this company?
Recent Insider Trading
No 3 month individual insider trading information.
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.